Side-by-side · Research reference

AHK-CuvsOvagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED14/43 cited

BTheoreticalHUMAN-REVIEWED2/42 cited

AHK-Cu

Tripeptide-Copper Complex · Cosmetic

10⁻¹² – 10⁻⁹ MActive range (in vitro)Pyo 2007

Dermal papilla cellsPrimary targetPyo 2007

TopicalRoute

Topical · Scalp / Skin

Ovagen

Khavinson Bioregulator · Ovarian

OvarianTarget tissue

Di/Tri-peptidePeptide length

AnimalEvidence tier

Oral / SQ · Protocol varies

01Mechanism of Action

Parameter

AHK-Cu

Ovagen

Primary target

Dermal papilla cells (DPCs) — specialized fibroblasts in hair follicle morphogenesisPyo 2007

Ovarian tissue chromatin complexes

Pathway

AHK-Cu → DPC proliferation → VEGF elevation, TGF-β1 suppression → Angiogenesis, follicle elongationPyo 2007

Tissue-specific peptide → Nuclear chromatin binding → Gene expression modulation → Cellular differentiation

Downstream effect

Stimulates hair follicle elongation ex vivo, reduces dermal papilla cell apoptosis, elevates Bcl-2/Bax ratio, reduces cleaved caspase-3 and PARPPyo 2007

Proposed ovarian functional support, fertility regulation, hormonal homeostasis restoration

Feedback intact?

—

Presumed physiological — Khavinson peptides described as regulatory, not replacement

Origin

Synthetic tripeptide with Cu²⁺ chelation — alanine substitution variant of GHK-Cu

Extracted from bovine/porcine ovarian tissue; short synthetic peptides (2–4 amino acids)

Antibody development

—

02Dosage Protocols

Parameter

AHK-Cu

Ovagen

Effective concentration (in vitro)

10⁻¹² – 10⁻⁹ MPyo 2007

Stimulated human hair follicle elongation ex vivo and DPC proliferation in vitro.

—

Topical formulation

0.001–0.01% (estimated cosmetic range)

No standardized human protocol published — extrapolated from in vitro data.

—

Frequency

Once or twice daily (topical application)

Once daily or cyclical (10–20 days per month)

Cyclical protocols common in Khavinson bioregulator tradition.

Route

Topical — scalp or dermal application

Oral (capsule) or subcutaneous

Oral absorption assumed for short peptides; SQ route mirrors other Khavinson bioregulators.

Evidence basis

Ex vivo hair follicle / in vitro DPC studiesPyo 2007

Theoretical / Russian-tradition

Duration

Not established — cosmetic protocols typically 8–12 weeks

4–12 weeks per cycle

Khavinson protocols typically 1–3 months; repeat cycles as needed.

Standard dose

—

10–20 mg / day (oral) or 1–2 mg SQ

Extrapolated from Khavinson-school protocols; no ovagen-specific PubMed dose studies.

04Side Effects & Safety

Parameter

AHK-Cu

Ovagen

Local irritation

Mild erythema, pruritus at application site (copper peptide class effect)

—

Copper sensitivity

Rare hypersensitivity reaction in copper-sensitive individuals

—

Systemic absorption

Minimal via topical route — systemic copper toxicity unlikely at cosmetic doses

—

Data limitations

No published human safety trials — cosmetic use presumed safe per class precedent (GHK-Cu)

—

Reported adverse events

—

None documented in indexed literature

Theoretical hormonal effects

—

Ovarian stimulation — monitor for estrogen-sensitive conditions

Injection site reaction

—

Possible mild erythema (SQ route)

Long-term safety

—

Unknown — no PubMed-indexed RCTs

Absolute Contraindications

AHK-Cu

·Known copper allergy or Wilson's disease

Ovagen

·Active hormone-sensitive malignancy (breast, ovarian, endometrial)
·Pregnancy

Relative Contraindications

AHK-Cu

·Broken or inflamed skin (increased absorption risk)
·Concurrent use of other copper-containing formulations

Ovagen

·History of estrogen-sensitive tumors (monitor)
·Polycystic ovary syndrome (PCOS) — theoretical ovarian hyperstimulation risk
·Endometriosis or fibroids (estrogen-responsive conditions)

05Administration Protocol

Parameter

AHK-Cu

Ovagen

1. Topical application

Apply to clean, dry scalp or target dermal area. Typical cosmetic formulations: 0.001–0.01% AHK-Cu in serum or cream base.

Typical dose: 10–20 mg once daily. Capsule form — taken on empty stomach, 20–30 min before meals. Khavinson tradition suggests morning administration.

2. Frequency

Once or twice daily. Evening application preferred for overnight contact time.

1–2 mg per injection. Reconstitute lyophilised powder with sterile water if required. Inject into abdomen or thigh; rotate sites.

3. Scalp preparation

For hair growth: apply directly to scalp, massage gently. No need to rinse. Allow absorption for minimum 2–4 hours.

Common pattern: 10–20 days on, 10 days off. Aligns with menstrual cycle phases in some protocols. Repeat cycles for 2–3 months, then assess.

4. Storage

Room temperature, protected from light. Copper complexes may degrade in UV exposure.

Lyophilised: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C, use within 7–14 days.

5. Duration

Minimum 8–12 weeks to assess efficacy in hair growth applications, per typical cosmetic peptide protocols.

—

06Stack Synergy

AHK-Cu

+ GHK-Cu

Moderate

View GHK-Cu →

Both tripeptide-copper complexes share overlapping angiogenic and wound-healing mechanisms (VEGF elevation, TGF-β modulation, fibroblast proliferation). AHK-Cu's alanine substitution may offer distinct receptor affinity or pharmacokinetics. Co-formulation could provide complementary dermal signaling, though no direct synergy studies exist. Often used interchangeably or in alternating protocols.

AHK-Cu: 0.001–0.01% topical · AM
GHK-Cu: 0.001–0.01% topical · PM
Frequency: Daily alternation or combined formulation
Primary benefit: Comprehensive dermal regeneration, angiogenesis, hair follicle support

Ovagen

— no documented stacks